(Q38163483)

30 August 2017

New agents in renal cell carcinoma (English)

1 reference

30 August 2017

Raetasha Dabney

1

1 reference

30 August 2017

Ryan Devine

series ordinal

2

1 reference

30 August 2017

Nancy Sein

series ordinal

3

1 reference

30 August 2017

Benjamin George

series ordinal

4

1 reference

30 August 2017

16 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

9

1 reference

30 August 2017

183-193

1 reference

30 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-013-0303-8

30 August 2017

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Cabozantinib as a novel therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0303-8

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

21 January 2018

1 reference

12 December 2020

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization

1 reference

12 December 2020

Pazopanib in renal cell carcinoma

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1007/S11523-013-0303-8

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference